About fate therapeutics inc - FATE
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
FATE At a Glance
Fate Therapeutics, Inc.
12278 Scripps Summit Drive
San Diego, California 92131
| Phone | 1-858-875-1800 | Revenue | 6.65M | |
| Industry | Biotechnology | Net Income | -136,315,000.00 | |
| Sector | Health Technology | Employees | 161 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
FATE Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 17.563 |
| Price to Book Ratio | 0.547 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.068 |
| Enterprise Value to Sales | -1.367 |
| Total Debt to Enterprise Value | -8.572 |
FATE Efficiency
| Revenue/Employee | 41,279.503 |
| Income Per Employee | -846,677.019 |
| Receivables Turnover | 4.113 |
| Total Asset Turnover | 0.017 |
FATE Liquidity
| Current Ratio | 5.786 |
| Quick Ratio | 5.786 |
| Cash Ratio | 5.646 |
FATE Profitability
| Gross Margin | -94.117 |
| Operating Margin | -2,205.898 |
| Pretax Margin | -2,051.083 |
| Net Margin | -2,051.083 |
| Return on Assets | -35.89 |
| Return on Equity | -51.84 |
| Return on Total Capital | -47.824 |
| Return on Invested Capital | -40.268 |
FATE Capital Structure
| Total Debt to Total Equity | 37.575 |
| Total Debt to Total Capital | 27.312 |
| Total Debt to Total Assets | 24.409 |
| Long-Term Debt to Equity | 35.373 |
| Long-Term Debt to Total Capital | 25.712 |